FDA approves AstraZeneca drug for severe asthma
The Food and Drug Administration has approved a new asthma medicine developed by AstraZeneca.
The drug, called Fasenra, was approved for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
Eosinophils are a type of disease-fighting white blood cell. A phenotype is the composite of an organism's observable characteristics or traits.
Asthma affects an estimated 315 million individuals worldwide, and up to 10 percents of asthma patients…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: Asthma | AstraZeneca | Biotechnology | Food and Drug Administration (FDA) | Health Management